MoonLake Immunotherapeutics (MLTX) Cash from Investing Activities (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $98000.0 for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 99.83% year-over-year to $98000.0; the TTM figure through Mar 2026 stood at $146.8 million (up 221.82% YoY), while the FY2025 annual figure was $203.0 million, up 198.73% from the prior year.
• Cash from Investing Activities was $98000.0 for Q1 2026 at MoonLake Immunotherapeutics, up from -$29.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $116.9 million in Q4 2023 to a low of -$174.4 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged -$3.5 million across 5 years, with a median of $98000.0 in 2026.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 362386.24% in 2022, then surged 633802550.0% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $9.9 million in 2022, then jumped by 1080.3% to $116.9 million in 2023, then slumped by 226.07% to -$147.3 million in 2024, then jumped by 79.7% to -$29.9 million in 2025, then jumped by 100.33% to $98000.0 in 2026.
• The last three Cash from Investing Activities figures came in at $98000.0 (Q1 2026), -$29.9 million (Q4 2025), and $88.4 million (Q3 2025), per Business Quant data.